Filing Details
- Accession Number:
- 0000950170-25-081041
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2025-06-03 16:46:15
- Reporting Period:
- 2025-06-02
- Filing Date:
- 2025-06-03
- Accepted Time:
- 2025-06-03 16:46:15
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1880438 | An2 Therapeutics Inc. | ANTX | Pharmaceutical Preparations (2834) | 820606654 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1914503 | Eric Easom | C/O An2 Therapeutics, Inc. 1800 El Camino Real, Suite D Menlo Park CA 94027 | Chief Executive Officer | No | No | No | No |
Transaction Summary
Purchased: | 10,000 shares | Avg. Price: $1.07 | Total Value: $10,665.00 |
Number of Shares After Transactions: | 256,380 shares |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2025-06-02 | 10,000 | $1.07 | 256,380 | No | 4 | P | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | P | Direct |
Reported Non-Derivative Holdings
Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
---|---|---|---|
Common Stock | 1,065,766 | Indirect | See Footnote |
Common Stock | 97,058 | Indirect | See Footnote |
Common Stock | 97,058 | Indirect | See Footnote |
Footnotes
- This price represents the weighted average purchase price for multiple transactions reported on this line. The prices of the transactions reported on this line ranged from $1.05 to $1.0699 per share. Upon request by the Commission staff, the issuer or a security holder of the issuer, the reporting person will undertake to provide full information regarding the number of shares sold at each separate price.
- Includes (i) 145,250 restricted stock units ("RSUs") which vest as follows: 1/4th of the shares vests annually over four years from January 1, 2025, subject to the Reporting Person's continuous service as of such date and (ii) a balance of 99,000 RSUs which vest as follows: 1/4th of the shares vests annually over four years from January 1, 2024, subject to the Reporting Person's continuous service as of each such date.
- Consists of shares of Common Stock held by the Easom Living Trust dated August 21, 2019.
- Consists of shares of Common Stock held by the C. Easom Irrevocable Trust dated October 8, 2021.
- Consists of shares of Common Stock held by the Jude Easom Irrevocable Trust dated October 8, 2021.